immunotherapies that are proving to be therapeutically beneficial for many patients, but not all, and at substantial cost in terms of toxicities and financial impact.
The past decade has seen remarkable progress in cancer treatment. Much of this has been due to the improvements in the ability to identify potentially targetable biomarkers. The identification of genetic aberrations has led to new therapies for lung cancer that are now achieving response rates approaching 90% in select patient subsets with tumors that are enriched for the specific target [1] . Better understanding of the pathways involved in immune tolerance and rejection have led to development of therapies to modulate those pathways and have turned previously untreatable cancers into chronic diseases.
After a slow start, we are now seeing an explosive growth in development of new drugs in these areas. In 2015 alone, there were no less than 32 approvals by the Food and Drug Administration (FDA) for new agents or new indications for existing agents in the treatment of various cancers [2] . The FDA has already granted 12 approvals for the first half of 2016.
While this rapid expansion offers new therapeutic options for patients where they did not exist before, it does not come without a cost.
Several of the recent FDA approvals have been for ''me-too'' drugs, agents that use a similar mechanism of action and with similar toxicity profiles as agents already on the market.
For example, nivolumab, an antibody that targets the Programmed Death (PD-1) receptor, which had already demonstrated activity in metastatic melanoma, was first approved in March 2015 for second-line therapy of advanced squamous non-small cell lung cancer (NSCLC) in patients progressing on or after prior platinum-based chemotherapy [3, 4] . In October, 2015, the FDA expanded nivolumab's indication to include NSCLCs of the adenocarcinoma variety as well [5, 6] . That same month, the FDA granted approval for pembrolizumab as second-line therapy in platinum-treated NSCLC patients, but with the requirement that they demonstrated positive Program Death Ligand 1 (PD-L1) expression [7, 8] for the first year of therapy [9] . Nivolumab monotherapy is approved for both squamous and non-squamous NSCLC as second-line therapy after prior platinum-based therapy, as noted earlier. This is based on the CheckMate trials comparing nivolumab versus docetaxel [4, 6] . Several countries have tried to analyze the cost-effectiveness of nivolumab in this setting. A United Kingdom study in 2015 reported that nivolumab in squamous NSCLC was not cost-effective per quality-adjusted life years (QALY) gained, and a similar Canadian study this year comparing nivolumab with docetaxel and erlotinib in NSCLC showed nivolumab with the highest per-patient cost [10, 11] . A more recent Swiss study looking at nivolumab versus docetaxel in non-squamous NSCLC using clinical data from the CheckMate-057 trial measured incremental cost effectiveness ratios (ICER) per QALY-gained [12] . The study showed that for all patients treated, nivolumab had much higher ICERs (in Swiss francs) than docetaxel; however, for patients with positive PD-L1 expression [[1% or [10% by immunohistochemical (IHC) staining], the nivolumab ICERs were lower and felt to be cost-effective based on a willingness-to-pay (WTP) threshold specific for the Swiss health-care system. Thus, the authors felt that for nivolumab to be cost-effective either the drug price and/or dose needed to be reduced or treatment based on PD-L1 testing should be considered.
Even for patients with good insurance coverage, this can be a daunting price tag. The economics of health care is complex and beyond the scope of this editorial. Health care policy is a moving target, but one that occupies a major component of our federal budget.
Reimbursement for medical care is moving towards value-based outcomes, rather than procedural or volume-based plans [13] .
Providers will not be paid for simply seeing more patients, ordering more tests, and delivering more treatments. [19, 20] . Patients uniformly say they would prefer and be more compliant with liquid biopsies as an alternative to tissue sampling if the accuracy of such testing was as good [21] .
Similarly, PRO assessment of quality of life metrics and toxicities can help define a value-based choice of treatment for a particular impact on their life. These added metrics, combined with clinical outcomes, could help determine the best value approach for a particular diagnosis and a patient centered care that would be cost effective as well. responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.
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